Net Sales are expected to increase by 14.1 percent Y-o-Y (up 4.8 percent Q-o-Q) to Rs 24,020 crore, according to Nirmal Bang.

"Bank Nifty will sustain its bullish momentum. The banking index on the weekly timeframe has witnessed a bullish breakout above its horizontal trend line, which is placed at 41,800 levels. "

"Bank Nifty will sustain its bullish momentum. The banking index on the weekly timeframe has witnessed a bullish breakout above its horizontal trend line, which is placed at 41,800 levels. "

In the last one month, Container Corporation Of India has gained about 16%

Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1820 in its research report dated October 25, 2022.

ICICI Direct recommended hold rating on Torrent Pharmaceuticals with a target price of Rs 1690 in its research report dated October 22, 2022.

Prabhudas Lilladher is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1850 in its research report dated October 25, 2022.

Torrent Pharmaceuticals Ltd., incorporated in the year 1972, is a Large Cap company (having a market cap of Rs 53383.00 Crore) operating in Pharmaceuticals sector.

Revenue from operations rose to Rs 2,291 crore in the July-September quarter as against Rs 2,137 crore in the year-ago period, Torrent Pharma said in a statement.

"Risk averseness will remain in the market for some time and to that extent, pharma is the only sector which did not perform as well in the overall up move. So to that extent, the ownership also and some of the companies have been giving decent numbers. Largecap pharma could actually outperform and that is something which should be the trade for a few weeks. "

ICICI Direct is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated September 28, 2022.

Anand Rathi is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1724 in its research report dated September 28, 2022.

Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated September 28, 2022.

The residential cycle has turned positive. Market fundamentals continue to be anchored around high affordability and market share continues to gravitate towards listed developers.

Torrent Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2022.

Prabhudas Lilladher is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1850 in its research report dated September 28, 2022.

Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 1500 in its research report dated September 27, 2022.

The domestic pharmaceutical player announced its acquisition of Curatio Healthcare for Rs 2,000 crore to strengthen its presence in the dermatology segment. It has entered into a definitive agreement to acquire 100 per cent stake, the company said in an exchange filing.

For the quarter ended June 30, 2022, the company has reported a consolidated total income of Rs 2377 crore, up 8.69 per cent from last quarter total income of Rs 2187 crore and up 9.34 per cent from last year same quarter total income of Rs 2174 crore.

​Citigroup maintained a ‘neutral on Torrent Pharma with a target price of Rs 1,700. India is growing at a CAGR of 16% over the last 10 years.

According to an exchange filing, the acquisition will add a field force of 600 MRs and a distribution network of 900 stockists

The transaction is subject to conditions precedent and is expected to close within one month, the pharma company said in a statement.

“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”

“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”

“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”

“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”

“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”

“Initially we are completely defying all global trends but let us see how long that lasts because it is very tough. The kind of moves Indian markets are giving are in complete contrast to emerging markets as well as world markets. The probability of that historically would not be more than 5%. Whether this 5% carries on is what we need to see.”

Set up in 1969 by Sami Khatib as Medley Laboratories, the Mumbai-based privately held company, now called Medley Pharmaceuticals, ranks among the top 40 pharmaceutical companies in India, as per research firm ORG IMS.

Set up in 1969 by Sami Khatib as Medley Laboratories, the Mumbai-based privately held company, now called Medley Pharmaceuticals, ranks among the top 40 pharmaceutical companies in India, as per research firm ORG IMS.

The transaction will see the exit of existing investors of Curatio, such as ChrysCapital (which holds a 20% stake) and Sequoia Capital (33%). Promoters, including GK Ramani, and the management will also be exiting the company.

During his tenure with Torrent Power, he has worked across different business segments of the company – namely Renewables, Thermal Generation and Distribution.

Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1820 in its research report dated July 29, 2022.